EU legislation just approved by legislators will require the European Commission to provide information on prices, manufacturers, delivery time frames and joint procurement processes for vaccines and medicines used in tackling future health crises such as pandemics.
The European Parliament has formally endorsed legislation that will allow the health authorities in the EU to better anticipate and respond to future health emergencies, including measures to improve the joint procurement and stockpiling of vaccines and medicines.
On 4 October, members of the parliament (MEPs) backed two draft regulations, one on serious cross-border threats to health, the...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.
